Oncology

Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

December 10, 2007
Jonathan Kolitz
Jonathan Kolitz

JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim results of this phase III trial from Jonathan Kolitz of Monter Cancer Center, Lake Success, NY, while George Canellos of the Dana-Farber Cancer Institute provided comment.

ASCO Logo Live Report from ASH:<br />Interleukin 2 For Acute Myeloid Leukemia In First Remission?

Download this interview

Add podcast to iTunes

Similar Interviews

  • Audio Journal of Hematologic Malignancy Special Edition 2005

    • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions, April

  • ASCO Audio Journal of Oncology – June 6th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6

    • Robert Mayer Thierry Facon

  • ASCO Audio Journal of Oncology – September 1st, 2006

    • Mark Socinski

    Post a comment